TP53 and neoplasm: In addition, prognostic and predictive co‐mutations (e.g., TP53, STK11, KEAP1) [43], as well as predictive biomarkers that require broad sequence coverage (e.g., tumor mutational burden), are further increasing the complexity of molecular diagnosis in aNSCLC.